Palisade Bio Q2 EPS $(0.53) Misses $(0.45) Estimate; Cash Balance of $16.4M to Fund Operations through 2024
Portfolio Pulse from Benzinga Newsdesk
Palisade Bio (NASDAQ:PALI) reported Q2 losses of $(0.53) per share, missing the analyst consensus estimate of $(0.45) by 17.78%. This is a 91.17% increase over losses of $(6.00) per share from the same period last year. The company has a cash balance of $16.4M to fund operations through 2024.
August 11, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Palisade Bio reported higher than expected losses for Q2, which could negatively impact investor sentiment. However, the company's cash balance should sustain operations until 2024.
Palisade Bio's higher than expected losses for Q2 could lead to a negative short-term reaction in the stock market. However, the company's cash balance, which is expected to fund operations until 2024, may mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100